Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 41 of 41 matching drugs for CD22 — including drugs targeting any of its 14 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
inotuzumab ozogamicin, flag (fludarabine, cytarabine and g-csf), hidac (high dose cytarabine), cytarabine and mitoxantrone CD22 Direct 1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LCK SSL via LCK 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LCK SSL via LCK 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK3 SSL via JAK3 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib TYK2 SSL via TYK2 2
nintedanib LCK SSL via LCK 2
nintedanib, pembrolizumab LCK SSL via LCK 2
afatinib, dasatinib, palbociclib, everolimus, olaparib LCK SSL via LCK 1
bevacizumab, dasatinib, placebo LCK SSL via LCK 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab LCK SSL via LCK 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin PRKAA1 SSL via PRKAA1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride LCK SSL via LCK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method LCK SSL via LCK 1
dasatinib, laboratory biomarker analysis, physiologic testing LCK SSL via LCK 1
dasatinib, mfolfox6 LCK SSL via LCK 1
dasatinib, pharmacological study LCK SSL via LCK 1
dasatinib, temozolomide, placebo, radiation therapy LCK SSL via LCK 1
lmb-100, tofacitinib, mesothelin expression JAK3 SSL via JAK3 1
lmb-100, tofacitinib, mesothelin expression TYK2 SSL via TYK2 1
ponatinib LCK SSL via LCK 1
ruxolitinib JAK3 SSL via JAK3 1
ruxolitinib TYK2 SSL via TYK2 1
ruxolitinib, erlotinib JAK3 SSL via JAK3 1
ruxolitinib, erlotinib TYK2 SSL via TYK2 1
ruxolitinib, radiation, temozolomide JAK3 SSL via JAK3 1
ruxolitinib, radiation, temozolomide TYK2 SSL via TYK2 1
trametinib, ruxolitinib JAK3 SSL via JAK3 1
trametinib, ruxolitinib TYK2 SSL via TYK2 1
trametinib, ruxolitinib, retifanlimab JAK3 SSL via JAK3 1
trametinib, ruxolitinib, retifanlimab TYK2 SSL via TYK2 1
baricitinib JAK3 SSL via JAK3 yes 0
dasatinib LCK SSL via LCK yes 0
pazopanib LCK SSL via LCK yes 0
pazopanib hydrochloride LCK SSL via LCK yes 0
tofacitinib JAK3 SSL via JAK3 yes 0
tofacitinib TYK2 SSL via TYK2 yes 0
tofacitinib citrate JAK3 SSL via JAK3 yes 0
tofacitinib citrate TYK2 SSL via TYK2 yes 0
upadacitinib JAK3 SSL via JAK3 yes 0
upadacitinib TYK2 SSL via TYK2 yes 0
vandetanib LCK SSL via LCK yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.